Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$14.00 -3.6%	$14.24	$10.57 ▼ $33.33	$2.11B	1.33	1.15 million shs	1.31 million shs
FATE Fate Therapeutics	$1.13 -1.7%	$1.21	$0.66 ▼ $5.92	$131.79M	2.18	2.17 million shs	972,860 shs
HALO Halozyme Therapeutics	$56.45 -2.4%	$54.29	$42.01 ▼ $70.51	$7.12B	1.15	1.75 million shs	1.11 million shs
VIR Vir Biotechnology	$5.41 -1.5%	$5.13	$4.32 ▼ $14.45	$758.93M	1.22	1.37 million shs	2.07 million shs
XLRN Acceleron Pharma	$178.75	$176.25	$108.82 ▼ $189.99	$10.93B	0.13	572,759 shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	-2.29%	-5.34%	+3.71%	+14.05%	-36.85%
FATE Fate Therapeutics	+1.77%	-0.86%	-4.17%	+3.60%	-74.22%
HALO Halozyme Therapeutics	-0.34%	+0.31%	+8.85%	-1.67%	+5.59%
VIR Vir Biotechnology	+1.48%	-7.42%	+7.65%	-0.18%	-46.54%
XLRN Acceleron Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.537 of 5 stars	4.5	1.0	0.0	4.7	2.7	3.3	0.0
FATE Fate Therapeutics	3.6619 of 5 stars	3.1	1.0	0.0	4.7	1.9	1.7	0.6
HALO Halozyme Therapeutics	4.9604 of 5 stars	3.1	4.0	0.0	4.4	2.9	2.5	4.4
VIR Vir Biotechnology	3.5865 of 5 stars	3.4	4.0	0.0	0.0	2.0	3.3	1.3
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	140.82% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	239.23% Upside
HALO Halozyme Therapeutics	2.17	Hold	$62.70	11.07% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	459.15% Upside
XLRN Acceleron Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest FATE, XLRN, HALO, DNLI, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$58.00 ➝ $60.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
7/10/2025	HALO Halozyme Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$55.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	6.15	N/A	N/A	$8.53 per share	1.64
FATE Fate Therapeutics	$13.63M	9.50	N/A	N/A	$2.80 per share	0.40
HALO Halozyme Therapeutics	$1.02B	6.85	$4.54 per share	12.43	$2.86 per share	19.74
VIR Vir Biotechnology	$74.21M	10.08	N/A	N/A	$8.35 per share	0.65
XLRN Acceleron Pharma	$92.52M	118.15	N/A	N/A	$11.74 per share	15.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$422.77M	-$2.67	0.00	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	0.00	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
HALO Halozyme Therapeutics	$444.09M	$3.76	13.63	9.08	0.39	44.76%	136.91%	26.05%	8/5/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	0.00	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)
XLRN Acceleron Pharma	-$166.03M	-$4.21	N/A	N/A	N/A	-226.01%	-32.11%	-29.45%	N/A

Latest FATE, XLRN, HALO, DNLI, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.34	N/A	N/A	N/A	$1.16 million	N/A
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	VIR Vir Biotechnology	-$0.83	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	HALO Halozyme Therapeutics	$1.22	N/A	N/A	N/A	$282.66 million	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.56	9.56
FATE Fate Therapeutics	N/A	8.81	8.81
HALO Halozyme Therapeutics	3.13	8.39	7.30
VIR Vir Biotechnology	N/A	6.79	6.79
XLRN Acceleron Pharma	N/A	12.14	12.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
FATE Fate Therapeutics	97.54%
HALO Halozyme Therapeutics	97.79%
VIR Vir Biotechnology	65.32%
XLRN Acceleron Pharma	90.35%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
FATE Fate Therapeutics	5.51%
HALO Halozyme Therapeutics	2.40%
VIR Vir Biotechnology	16.00%
XLRN Acceleron Pharma	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
HALO Halozyme Therapeutics	390	123.22 million	120.26 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable
XLRN Acceleron Pharma	312	61.16 million	60.12 million	Optionable

FATE, XLRN, HALO, DNLI, and VIR Headlines

Recent News About These Companies

Acceleron P Stock Price Today | NASDAQ: XLRN Live - Investing.com

June 28, 2025 | investing.com

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

January 2, 2025 | benzinga.com

Acceleron advances cold fusion technology

December 17, 2024 | neimagazine.comN

Acceleron Banks on Muons for Colder Fusion

December 6, 2024 | msn.com

Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study

November 26, 2024 | fiercepharma.comF

Acceleron attracts turbocharged demand for debut Swissie

October 17, 2024 | globalcapital.comG

Acceleron Fusion has raised $15M to take a stab at colder fusion, filing reveals

October 5, 2024 | techcrunch.comT

Acceleron Fusion has raised $15M to take another stab at cold fusion, filing reveals

October 1, 2024 | yahoo.com

Merck confirms $11.5bn Acceleron takeover deal

August 6, 2024 | pharmaphorum.comP

Earnings to Watch Next Week: ON Semiconductor, Ferrari, General Motors and Moderna in Focus

April 26, 2024 | fxempire.comF

Big Pharma Q1 earnings roundup: AstraZeneca, BMS, Merck, Sanofi

April 26, 2024 | mmm-online.comM

ORBIMED CAPITAL GP II LLC's Net Worth

February 27, 2024 | benzinga.com

XLRN Historical Data

October 20, 2023 | investing.com

MSD eyes March FDA decision on PAH drug sotatercept

October 15, 2023 | pharmaphorum.comP

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

April 15, 2023 | thestreet.com

Astellas Pharma Inc

March 17, 2023 | reuters.com

HempStreet partners with MGC Pharma launches ArtemiC

January 30, 2023 | health.economictimes.indiatimes.com

Acceleron Corp Becomes a Digital Correspondent Bank

December 14, 2022 | finance.yahoo.com

Pharma Contract Sales Market Report 2022-2032

November 30, 2022 | finance.yahoo.com

Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs

November 21, 2022 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, XLRN, HALO, DNLI, and VIR Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$14.00 -0.53 (-3.65%)

Closing price 04:00 PM Eastern

Extended Trading

$14.00 -0.01 (-0.04%)

As of 07:57 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Fate Therapeutics NASDAQ:FATE

$1.13 -0.02 (-1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.05 (+4.34%)

As of 07:55 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Halozyme Therapeutics NASDAQ:HALO

$56.45 -1.36 (-2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$56.44 -0.01 (-0.01%)

As of 07:01 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Vir Biotechnology NASDAQ:VIR

$5.41 -0.08 (-1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$5.41 0.00 (0.00%)

As of 06:39 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Acceleron Pharma NASDAQ:XLRN

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time